Stockreport

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Mineralys Therapeutics, Inc.  (MLYS) 
PDF – Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 – – Completed enrollment in Explore-OSA trial; topline results anticipated in [Read more]